New Auvelity Data; Yale’s Mental Health Lawsuit; Depression Nasal Spray Fast-Tracked

The antidepressant dextromethorphan HBr-bupropion HCl (Auvelity) achieved rapid and sustained improvements in both cognitive and physical functioning in people with major depressive disorder in the 12-month EVOLVE trial, Axsome Therapeutics announced.

Having at least one outpatient behavioral health treatment visit cut the amount of overall medical spending for patients with a newly diagnosed behavioral health condition. (JAMA Network Open)

Could the DSM-5 diagnosis for post-traumatic stress disorder (PTSD) be causing vast heterogeneity of cases? (JAMA Psychiatry)

Students filed a federal lawsuit against Yale University for alleged “systemic discrimination” against students with mental health disabilities. (NBC News)

People in a Danish study diagnosed with a mental illness lost an average 10.5 years of working life versus the general population — mostly stemming from longer stretches of unemployment and time receiving a disability pension. (The Lancet Psychiatry)

The FDA granted fast track designation for the investigational pherine nasal spray PH10 for major depressive disorder, Vistagen announced.

Very few youth with anxiety started pharmacotherapy after not fully responding to cognitive behavioral therapy, despite pharmacotherapy being associated with significant improvement in symptoms. (Journal of Clinical Psychiatry)

An analysis of wastewater in a Massachusetts college town uncovered a rise in the use of drugs including fentanyl and amphetamines early on in the pandemic. The biggest increase was marked by a 286% rise in MDMA use. (Society for Risk Analysis Annual Meeting)

Biogen and Sage Therapeutics announced that zuranolone’s new drug application for major depressive disorder has officially been sent over to the FDA.